Synaptic plasticity, the basic mechanism of clinical recovery after brain lesion, can also remarkably influence the clinical course of multiple sclerosis (MS). Physical rehabilitation represents the main treatment option to promote synaptic long-term potentiation (LTP) and to enhance spontaneous recovery of neurological deficits.
Objectives:
To overview the role of pharmacological treatment and physical rehabilitation in modulating LTP and enhancing clinical recovery in MS.
Results:
Drug-induced LTP enhancement can be effectively used to promote functional recovery, alone or combined with rehabilitation. Also, as inflammatory cytokines alter synaptic transmission and plasticity in MS, pharmacological resolution of inflammation can positively influence clinical recovery. Finally, physical exercise could be an independent factor able to preserve or enhance LTP reserve both influencing signaling pathways involved in plasticity induction and maintenance, and decreasing inflammation.
Future directions:
Better knowledge of LTP determinants may be useful to design specific strategies to promote recovery after a relapse and to reduce the progressive neurological deterioration in MS patients.
CentonzeDRossiSTortiglioneAet al. Synaptic plasticity during recovery from permanent occlusion of the middle cerebral artery. Neurobiol Dis2007; 27: 44–53.
Di LazzaroVProficePPilatoFet al. Motor cortex plasticity predicts recovery in acute stroke. Cereb Cortex2010; 20: 1523–1528.
4.
MoriFKusayanagiHNicolettiCGet al. Cortical plasticity predicts recovery from relapse in multiple sclerosis. Mult Scler2014; 20: 451–457.
5.
MoriFRossiSPiccininSet al. Synaptic plasticity and PDGF signaling defects underlie clinical progression in multiple sclerosis. J Neurosci2013; 33: 19112–19119.
6.
ZiemannUIlićTVPauliCet al. Learning modifies subsequent induction of long-term potentiation-like and long-term depression-like plasticity in human motor cortex. J Neurosci2004; 24(7): 1666–1672.
7.
BiernaskieJCorbettD.Enriched rehabilitative training promotes improved forelimb motor function and enhanced dendritic growth after focal ischemic injury. J Neurosci2001; 21(14): 5272–5280.
8.
RossiSFurlanRDe ChiaraVet al. Exercise attenuates the clinical, synaptic and dendritic abnormalities of experimental autoimmune encephalomyelitis. Neurobiol Dis2009; 36(1): 51–59.
9.
BlissTVCollingridgeGL.A synaptic model of memory: Long-term potentiation in the hippocampus. Nature1993; 361(6407): 31–39.
10.
HuangYZChenRSRothwellJCet al. The after-effect of human theta burst stimulation is NMDA receptor dependent. Clin Neurophysiol2007; 118(5): 1028–1032.
11.
SchwenkreisPWitscherKPlegerB.The NMDA antagonist memantine affects training induced motor cortex plasticity-a study using transcranial magnetic stimulation. BMC Neurosci2000; 6: 35.
12.
VillosladaPArrondoGSepulcreJet al. Memantine induces reversible neurologic impairment in patients with MS. Neurology2009; 72(19): 1630–1633.
13.
D’AnielloAVetereAPetrucelliL.Further study on the specificity of D-amino acid oxidase and D-aspartate oxidase and time course for complete oxidation of D-amino acids. Comp Biochem Physiol B1993; 105: 731–734.
HeifetsBDCastilloPE.Endocannabinoid signaling and long-term synaptic plasticity. Annu Rev Physiol2009; 71: 283–306.
16.
MadroñalNGruartAValverdeOet al. Involvement of cannabinoid CB1 receptor in associative learning and in hippocampal CA3-CA1 synaptic plasticity. Cereb Cortex2012; 22(3): 550–566.
17.
KochGMoriFCodecàCet al. Cannabis-based treatment induces polarity-reversing plasticity assessed by theta burst stimulation in humans. Brain Stimul2009; 2(4): 229–233.
18.
HeymanEGamelinFXAucouturierJet al. The role of the endocannabinoid system in skeletal muscle and metabolic adaptations to exercise: Potential implications for the treatment of obesity. Obes Rev2012; 13(12): 1110–1124.
19.
MoriFLjokaCNicolettiCGet al. CB1 receptor affects cortical plasticity and response to physiotherapy in multiple sclerosis. Neurol Neuroimmunol Neuroinflamm2014; 1(4): e48.
20.
HuangYYKandelER.D1/D5 receptor agonists induce a protein synthesis-dependent late potentiation in the CA1 region of the hippocampus. Proc Natl Acad Sci U S A1995; 92(7): 2446–2450.
21.
MeintzschelFZiemannU.Modification of practice-dependent plasticity in human motor cortex by neuromodulators. Cereb Cortex2006; 16(8): 1106–1115.
22.
UekiYMimaTKotbMAet al. Altered plasticity of the human motor cortex in Parkinson’s disease. Ann Neurol2006; 59(1): 60–71.
23.
ScheidtmannKFriesWMüllerFet al. Effect of levodopa in combination with physiotherapy on functional motor recovery after stroke: A prospective, randomised, double-blind study. Lancet2001; 358(9284): 787–790.
24.
RösserNHeuschmannPWerschingHet al. Levodopa improves procedural motor learning in chronic stroke patients. Arch Phys Med Rehabil2008; 89(9): 1633–1641.
25.
TanakaJHoriikeYMatsuzakiMet al. Protein synthesis and neurotrophin-dependent structural plasticity of single dendritic spines. Science2008; 319(5870): 1683–1687.
26.
CheeranBTalelliPMoriFet al. A common polymorphism in the brain-derived neurotrophic factor gene (BDNF) modulates human cortical plasticity and the response to rTMS. J Physiol2008; 586(23): 5717–5725.
27.
KleimJAChanSPringleEet al. BDNF val66met polymorphism is associated with modified experience-dependent plasticity in human motor cortex. Nat Neurosci2006; 9(6): 735–737.
28.
KimWSLimJYShinJHet al. Effect of the presence of brain-derived neurotrophic factor val(66)met polymorphism on the recovery in patients with acute subcortical stroke. Ann Rehabil Med2013; 37(3): 311–319.
29.
KarpovaNNPickenhagenALindholmJet al. Fear erasure in mice requires synergy between antidepressant drugs and extinction training. Science2011; 334(6063): 1731–1734.
30.
DamMToninPDe BoniAet al. Effects of fluoxetine and maprotiline on functional recovery in poststroke hemiplegic patients undergoing rehabilitation therapy. Stroke1996; 27(7): 1211–1214.
31.
CambronMMostertJHaentjensPet al. Fluoxetine in progressive multiple sclerosis (FLUOX-PMS): Study protocol for a randomized controlled trial. Trials2014; 15: 37.
32.
GoldSMSchulzKHHartmannSet al. Basal serum levels and reactivity of nerve growth factor and brain-derived neurotrophic factor to standardized acute exercise in multiple sclerosis and controls. J Neuroimmunol2003; 138(1–2): 99–105.
33.
RossiSStuderVMottaCet al. Cerebrospinal fluid detection of interleukin-1β in phase of remission predicts disease progression in multiple sclerosis. J Neuroinflamm2014; 11: 32.
34.
CentonzeDBariMRossiSet al. The endocannabinoid system is dysregulated in multiple sclerosis and in experimental autoimmune encephalomyelitis. Brain2007; 130(Pt 10): 2543–2553.
35.
TongiorgiESartoriABajGet al. Altered serum content of brain-derived neurotrophic factor isoforms in multiple sclerosis. J Neurol Sci2012; 320(1–2): 161–165.
36.
Di FilippoMde IureAGiampàCet al. Persistent activation of microglia and NADPH oxidase drive hippocampal dysfunction in experimental multiple sclerosis. Sci Rep2016; 6: 20926.
37.
MoriFKusayanagiHButtariFet al. Early treatment with high-dose interferon beta-1a reverses cognitive and cortical plasticity deficits in multiple sclerosis. Funct Neurol2012; 27(3): 163–168.
38.
BernardesDOliveira-LimaOCSilvaTVet al. Differential brain and spinal cord cytokine and BDNF levels in experimental autoimmune encephalomyelitis are modulated by prior and regular exercise. J Neuroimmunol2013; 264(1–2): 24–34.
